JP4869540B2 - 経皮的製剤送達用組成物 - Google Patents

経皮的製剤送達用組成物 Download PDF

Info

Publication number
JP4869540B2
JP4869540B2 JP2002522855A JP2002522855A JP4869540B2 JP 4869540 B2 JP4869540 B2 JP 4869540B2 JP 2002522855 A JP2002522855 A JP 2002522855A JP 2002522855 A JP2002522855 A JP 2002522855A JP 4869540 B2 JP4869540 B2 JP 4869540B2
Authority
JP
Japan
Prior art keywords
nitrite
acid
pharmacologically acceptable
skin
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002522855A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004507486A5 (https=
JP2004507486A (ja
Inventor
アーサー チューダー タッカー
ニゲル ベンジャミン
Original Assignee
クイーン マリイ アンド ウェストフィールド カレッジ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クイーン マリイ アンド ウェストフィールド カレッジ filed Critical クイーン マリイ アンド ウェストフィールド カレッジ
Publication of JP2004507486A publication Critical patent/JP2004507486A/ja
Publication of JP2004507486A5 publication Critical patent/JP2004507486A5/ja
Application granted granted Critical
Publication of JP4869540B2 publication Critical patent/JP4869540B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2002522855A 2000-08-30 2001-08-30 経皮的製剤送達用組成物 Expired - Fee Related JP4869540B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0021317.3 2000-08-30
GBGB0021317.3A GB0021317D0 (en) 2000-08-30 2000-08-30 Transdermal pharmaceutical delivery composition
PCT/GB2001/003863 WO2002017881A2 (en) 2000-08-30 2001-08-30 Transdermal pharmaceutical delivery composition

Publications (3)

Publication Number Publication Date
JP2004507486A JP2004507486A (ja) 2004-03-11
JP2004507486A5 JP2004507486A5 (https=) 2008-10-16
JP4869540B2 true JP4869540B2 (ja) 2012-02-08

Family

ID=9898548

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002522855A Expired - Fee Related JP4869540B2 (ja) 2000-08-30 2001-08-30 経皮的製剤送達用組成物

Country Status (9)

Country Link
US (4) US8128964B2 (https=)
EP (1) EP1328252B1 (https=)
JP (1) JP4869540B2 (https=)
AT (1) ATE347879T1 (https=)
AU (2) AU8419101A (https=)
DE (1) DE60125217T2 (https=)
ES (1) ES2275716T3 (https=)
GB (1) GB0021317D0 (https=)
WO (1) WO2002017881A2 (https=)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0021317D0 (en) * 2000-08-30 2000-10-18 Queen Mary & Westfield College Transdermal pharmaceutical delivery composition
ES2294543T3 (es) 2003-07-09 2008-04-01 The Government Of The United States Of America, As Represented By The Secretary, Department Of Heal Uso de sales de nitrilo para el tratamiento de afecciones cardiovasculares.
WO2006084911A2 (en) * 2005-02-11 2006-08-17 Nolabs Ab Improved device for application of medicaments, manufacturing method therefor, and method of treatment
WO2006125123A2 (en) * 2005-05-19 2006-11-23 University Of Cincinnati Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite
ES2731298T3 (es) 2005-05-27 2019-11-14 Univ North Carolina Chapel Hill Partículas de liberación de óxido nítrico para agentes terapéuticos de óxido nítrico y aplicaciones biomédicas
GB0607402D0 (en) 2006-04-12 2006-05-24 Barts & London Nhs Trust Therapeutic composition and use
US8445018B2 (en) * 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US20090112197A1 (en) 2007-10-30 2009-04-30 Searete Llc Devices configured to facilitate release of nitric oxide
US8642093B2 (en) 2007-10-30 2014-02-04 The Invention Science Fund I, Llc Methods and systems for use of photolyzable nitric oxide donors
US20110190604A1 (en) * 2006-12-22 2011-08-04 Hyde Roderick A Nitric oxide sensors and systems
US7862598B2 (en) * 2007-10-30 2011-01-04 The Invention Science Fund I, Llc Devices and systems that deliver nitric oxide
US8221690B2 (en) 2007-10-30 2012-07-17 The Invention Science Fund I, Llc Systems and devices that utilize photolyzable nitric oxide donors
US20090110933A1 (en) * 2007-10-30 2009-04-30 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems and devices related to nitric oxide releasing materials
US20090130233A1 (en) * 2007-10-24 2009-05-21 Baker Christopher G Two part lotion
US10080823B2 (en) 2007-10-30 2018-09-25 Gearbox Llc Substrates for nitric oxide releasing devices
US8349262B2 (en) 2007-10-30 2013-01-08 The Invention Science Fund I, Llc Nitric oxide permeable housings
US7897399B2 (en) 2007-10-30 2011-03-01 The Invention Science Fund I, Llc Nitric oxide sensors and systems
US8877508B2 (en) * 2007-10-30 2014-11-04 The Invention Science Fund I, Llc Devices and systems that deliver nitric oxide
US8980332B2 (en) 2007-10-30 2015-03-17 The Invention Science Fund I, Llc Methods and systems for use of photolyzable nitric oxide donors
US8303995B1 (en) * 2008-06-13 2012-11-06 Board Of Regents, The University Of Texas System Nitrite formulations and their use as nitric oxide prodrugs
BRPI0913809B1 (pt) * 2008-10-02 2019-02-05 Mylan Inc método para produzir continuamente um laminado adesivo sensível á pressão multicamada
EP2334279A4 (en) * 2008-10-16 2013-03-20 Novan Inc STAIN OXIDE RELEASING PARTICLES FOR MOUTH CARE APPLICATIONS
GB0901456D0 (en) * 2009-01-29 2009-03-11 Insense Ltd Treatment of psoriasis
US9241999B2 (en) * 2009-06-15 2016-01-26 Board Of Regents Of The University Of Texas System Method of producing physiological and therapeutic levels of nitric oxide through an oral delivery system
WO2011022652A1 (en) 2009-08-21 2011-02-24 Novan, Inc. Topical gels
CA2771389C (en) 2009-08-21 2019-04-09 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
BR112012008508A2 (pt) * 2009-10-13 2017-06-13 Novan Inc revestimento de sol-gel, substrato, método para produzir um revestimento de sol-gel
RU2445918C1 (ru) * 2010-07-15 2012-03-27 Федеральное государственное образовательное учреждение высшего профессионального образования Санкт-Петербургский государственный университет Способ неинвазивной дифференциальной диагностики патологии лимфатических и венозных сосудов нижних конечностей
PT2533773E (pt) 2010-10-21 2015-12-01 Kipax Ab Dispositivo de administração de óxido nítrico por via cutânea tópica
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
WO2012118829A2 (en) 2011-02-28 2012-09-07 Novan, Inc. Tertiary s-nitrosothiol-modified nitricoxide-releasing xerogels and methods of using the same
EP2691087A2 (en) 2011-03-31 2014-02-05 László Gábor Szabó Pharmaceutical composition containing no, process for the preparation and use thereof
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10517817B2 (en) 2013-05-09 2019-12-31 Syk Technologies, Llc Deep topical systemic nitric oxide therapy apparatus and method
GB201309092D0 (en) * 2013-05-20 2013-07-03 Edixomed Ltd Transdermal delivery system
GB201309091D0 (en) * 2013-05-20 2013-07-03 Edixomed Ltd Dressing system
US11406769B2 (en) * 2014-01-31 2022-08-09 Galderma Holding SA Lubrication of an injection needle
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US10322082B2 (en) 2014-07-11 2019-06-18 Novan, Inc. Topical antiviral compositions and methods of using the same
CN106659675B (zh) 2014-07-11 2023-07-04 诺万公司 局部抗病毒组合物和其使用方法
WO2016010988A1 (en) 2014-07-14 2016-01-21 Novan, Inc. Nitric oxide releasing nail coating compositions, nitric oxide releasing nail coatings, and methods of using the same
GB201420761D0 (en) 2014-11-21 2015-01-07 Edixomed Ltd And First Water Ltd Dressing system
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10849864B2 (en) 2015-07-28 2020-12-01 Novan, Inc. Combinations and methods for the treatment and/or prevention of fungal infections
GB201520990D0 (en) 2015-11-27 2016-01-13 Edixomed Ltd Dressing system
WO2017132275A1 (en) 2016-01-27 2017-08-03 Syk Technologies, Llc Nitric oxide topical application apparatus and methods
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US10149843B1 (en) 2017-02-07 2018-12-11 Gneus Lifescineces Inc. Pharmaceutical compositions and methods of using the same
US10231961B1 (en) 2017-02-07 2019-03-19 Genus Lifesciences Inc. Pharmaceutical compositions and methods of using the same
US10413505B1 (en) 2017-02-07 2019-09-17 Genus Lifesciences Inc. Pharmaceutical compositions and methods of using the same
BR112021023632A2 (pt) 2019-06-04 2022-04-19 Thirty Respiratory Ltd Métodos e composições para gerar óxido nítrico e usos do mesmo para entregar óxido nítrico através do trato respiratório
BR112021023832A8 (pt) * 2019-06-04 2023-02-28 Thirty Holdings Ltd Métodos e composições para geração de óxido nítrico e usos dos mesmos
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
JP2023526583A (ja) 2020-04-23 2023-06-22 サーティー レスピラトリー リミテッド 結核を治療及び抑制するための方法及び組成物
US20240016831A1 (en) 2020-04-23 2024-01-18 Thirty Respiratory Limited Nitric oxide or nitric oxide releasing compositions for use in treating sars-cov and sars-cov-2
US12459820B2 (en) 2020-06-11 2025-11-04 J. W. Randolph Miller Stabilized and NO2-inhibited nitric oxide generating gels for inhaled nitric oxide therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58913A (ja) 1981-06-26 1983-01-06 Nitto Electric Ind Co Ltd 局所系医薬製剤
RO92445B1 (ro) * 1985-08-12 1987-10-01 Ludovic L. Elthes Unguent medicamentos cu actiune antiinflamatoare, cicatrizanta si epitelizanta
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
JPH07108849B2 (ja) 1991-02-08 1995-11-22 奈良炭化工業株式会社 葉面散布用植物成育剤
US5264219A (en) * 1992-08-07 1993-11-23 Minnesota Mining And Manufacturing Company Transdermal drug delivery backing
US5891846A (en) * 1994-02-17 1999-04-06 Shiseido Company, Ltd. Cyclosporin-containing emulsion composition
GB9804469D0 (en) 1998-03-02 1998-04-29 Univ Aberdeen Antiviral composition
BR9507099A (pt) 1994-02-21 1997-09-16 Aberden University Forma de dosagem método de esterilização composição esterilizante e suplemento alimentar animal compreendendo nitrito acidificado como um agente anti-microbiano
US5648101A (en) * 1994-11-14 1997-07-15 Tawashi; Rashad Drug delivery of nitric oxide
SE9700617D0 (sv) 1997-02-21 1997-02-21 Kjell Alving New composition
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US5900249A (en) * 1998-02-09 1999-05-04 Smith; David J. Multicomponent pain relief topical medication
US6103275A (en) * 1998-06-10 2000-08-15 Nitric Oxide Solutions Systems and methods for topical treatment with nitric oxide
GB0021317D0 (en) * 2000-08-30 2000-10-18 Queen Mary & Westfield College Transdermal pharmaceutical delivery composition

Also Published As

Publication number Publication date
US20040013747A1 (en) 2004-01-22
US20120183595A1 (en) 2012-07-19
EP1328252B1 (en) 2006-12-13
GB0021317D0 (en) 2000-10-18
AU2001284191B2 (en) 2006-02-16
US20090036491A1 (en) 2009-02-05
DE60125217T2 (de) 2007-10-25
DE60125217D1 (de) 2007-01-25
ATE347879T1 (de) 2007-01-15
WO2002017881A2 (en) 2002-03-07
EP1328252A2 (en) 2003-07-23
US8128964B2 (en) 2012-03-06
ES2275716T3 (es) 2007-06-16
WO2002017881A3 (en) 2003-04-17
AU2001284191C1 (en) 2002-03-13
US8114442B2 (en) 2012-02-14
AU8419101A (en) 2002-03-13
JP2004507486A (ja) 2004-03-11
US20140187481A1 (en) 2014-07-03

Similar Documents

Publication Publication Date Title
JP4869540B2 (ja) 経皮的製剤送達用組成物
AU2001284191A1 (en) Transdermal pharmaceutical delivery composition
ES2326729T3 (es) Composicion farmaceutica que contiene una fuente de nitrato y un agente acidificante para tratar heridas abiertas y quemaduras.
US9968635B2 (en) Treatment of skin and soft tissue infection with nitric oxide
US9844565B2 (en) Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
Maunuksela et al. Double-blind evaluation of a lignocaine-prilocaine cream (EMLA) in children: effect on the pain associated with venous cannulation
US10034898B2 (en) Methods and systems for treatment of inflammatory diseases with nitric oxide
JP2006522822A (ja) アルコールを含まない経皮インスリン組成物およびその製造工程ならびに使用
Doyle et al. An evaluation of a new self‐adhesive patch preparation of amethocaine for topical anaesthesia prior to venous cannulation in children
US20050142218A1 (en) Pharmaceutical composition containing nitrate source and an acidifying agent for treating skin ischaemia
Giordano et al. Local anesthesia: evidence, strategies, and safety
US7291591B2 (en) Alcohol-free transdermal insulin composition
US10272039B2 (en) Topical sodium nitrite formulation
Tucker et al. Study of a combined percutaneous local anaesthetic and nitric oxide‐generating system for venepuncture
Mohite et al. Route of Administration of Drugs

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20050420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080822

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080822

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111109

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111116

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141125

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees